The Kiso pilot study is a randomized controlled trial to test the acceptability and feasibility of a novel digital intervention, namely the Kiso Mind smartphone app. A parallel-group design is utilized. Participants either receive access to the Kiso Mind intervention and treatment-as-usual (TAU) in the experimental condition or receive treatment as usual (TAU) in the control condition. The intervention is designed for participants diagnosed with either schizophrenia (F20.0) or schizoaffective disorder (F25.0) according to the ICD-10. To examine acceptability, feasibility, and preliminary effectiveness, both self-report and rater-based assessments are administered at baseline (T0) and at the end of the 12-week intervention period (post-intervention T1). Lastly, a qualitative interview will be conducted with participants from the experimental condition. The primary outcome of the present study is the acceptability and feasibility of the Kiso Mind app. The secondary outcome consists of general psychopathology, and positive-, negative-, depressive symptoms, as well as social functioning and self-efficacy ratings.
There are multiple ways to join the present study. Healthcare workers at different institutions across Germany identify eligible participants and invite them to participate in the study. Those institutions include inpatient wards and outpatient facilities. Moreover, participants can join via multiple channels, including online channels and advertising such as social media, etc. Eligibility screenings and baseline clinician ratings are conducted centrally by research associates (psychologists) at Charité Universitätsmedizin Berlin via a video interview. After confirming the inclusion criteria, participants will be randomised and receive the self-report section of the baseline assessment. Randomization is conducted independently by research associates at the Universitätsklinikum Hamburg-Eppendorf in Hamburg. After 12 weeks, participants complete a clinical interview to assess the rater-based section of the post-treatment assessment and receive the self-report section via email. All participant data is stored in a pseudonymized format. No clinical data is saved in combination with clinical data. The participants have the right to access their data and the right to claim deletion of their data. Data are stored in an online database, accessible only to researchers involved in the study. Due to the exploratory nature of this study, we aim to recruit 60 to 80 participants in total until June.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
See above.
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, Germany
RECRUITINGProportion of PP receiving threshold dose (Acceptability)
The proportion of modules completed on average by all participants.
Time frame: 12 weeks
Nr. of pp willing to participate (Feasibility)
The number of eligible participants, that are willing to participate in Kiso (recruitment)
Time frame: 12 weeks
Clinical Global Impression (T0; T1)
Assesses overall clinical illness severity as judged by the clinician, providing a global rating of the patient's current level of psychopathology. (Scores: 1 to 7; higher scores = higher illness severity)
Time frame: 12 weeks
Patient Global Impression (T0; T1)
Description: Assesses overall clinical illness severity as judged by the patients, providing a global rating of the patient's perceived current level of psychopathology. (Scores: 1 to 5; higher scores = higher perceived illness severity)
Time frame: 12 weeks
Community Assessment of Psychic Experiences (CAPE) (T0, T1)
Assesses the frequency and distress associated with psychotic-like experiences in the general population, covering positive, negative, and depressive symptom dimensions. (Scores: 0 to 96; higher scores = higher frequency of psychotic-like experiences AND Scores: 0 to 96; higher scores = higher distress of psychotic like experiences)
Time frame: 12 weeks
Beck Depressions-Inventar (BDI-II) (T0, T1)
A 21-item self-report questionnaire measuring the severity of depressive symptoms over the past two weeks. (Scores: 0 to 63; higher scores = higher severity of depressive symptoms)
Time frame: 12 weeks
Brief Symptom Inventory (BSI) (T0, T1)
A self-report measure assessing general psychological distress across multiple symptom domains (e.g., depression, anxiety, somatization). (Scores: 0 to 212; higher scores = higher self-reported general psychological distress)
Time frame: 12 weeks
General Self-Efficacy Scale (GSE) (T0, T1)
Measures perceived self-efficacy, reflecting an individual's belief in their ability to cope with difficult demands and challenges. (Scores: 4 to 40; higher scores = higher self-efficacy)
Time frame: 12 weeks
Social Functioning Scale (SFS) (T0, T1)
Assesses social functioning and role performance, including social engagement, interpersonal behavior, and independent living skills.
Time frame: 12 weeks
EQ-5D Quality of life questionnaire (T0, T1)
A standardized measure of health-related quality of life, covering mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. (Scores: 5 to 25; higher scores = lower health-related quality of life)
Time frame: 12 weeks
Patient Satisfaction Questionnaire (ZUF-8) (T1, Experimental Group)
Evaluates patient satisfaction with treatment or services, focusing on perceived quality, usefulness, and overall satisfaction. (Scores: 4 to 28; higher scores = higher patient satisfaction)
Time frame: 12 weeks
System Usability Scale (SUS) (T1, Experimental Group)
A 10-item questionnaire assessing perceived usability and user-friendliness of a system or digital intervention.
Time frame: 12 weeks
Negative Effects Questionnaire (NEQ) (T1, Experimental Group)
Assesses adverse and unwanted effects of psychological treatment, including symptom worsening, dependency, or emotional distress. (Scores: 0 to 116; higher scores = higher severity of unwanted effects)
Time frame: 12 weeks
Medication Adherence Report Scale (MARS-5) (T0, T1)
A self-report measure assessing medication adherence behavior, including intentional and unintentional non-adherence. (Scores: 5 to 25; higher scores = higher medication non-adherence)
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.